Valproate lamotrigine — GPhC CRA MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: B — Increased lamotrigine exposure and rash risk
This scenario assesses Valproate lamotrigine in a UK pharmacy practice context. Valproate inhibits lamotrigine metabolism and rapid titration increases serious rash risk. The best answer is Increased lamotrigine exposure and rash risk because it addresses the principal clinical, legal or safety issue before routine supply. The other options are less appropriate because they either miss the key risk, delay necessary review, or would not meet expected BNF, NICE, MEP, MHRA or GPhC practice standards.
Reference: https://www.pharmacyregulation.org/registration-assessment#stage-8-order-69